Targeting of Fn14 prevents cancer-induced cachexia and prolongs survival
Lynch, GS; Anderton, H; Silke, J; Laine, D; Casey, JL; Tanzer, M; Schloegel, J; Sahay, T; Dillon, H; Weston, R; Liu, SY; Wong, WW; Talbo, G; Schneider, P; Scott, AM; Hoogenraad, J; Gregorevic, P; Foley, M; Jayatilleke, KM; Johnston, AJ; Faou, P; Emmrich, K; Hoogenraad, NJ; Levina, V; Burkly, LC; Jenkinson, L; Murphy, KT; Hall, C
Abstract
The cytokine TWEAK and its cognate receptor Fn14 are members of the TNF/TNFR superfamily and are upregulated in tumors. We found that Fn14, when expressed in tumors, causes cachexia and that antibodies against Fn14 dramatically extended lifespan by inhibiting tumor-induced weight loss although having only moderate inhibitory effects on tumor growth. Anti-Fn14 antibodies prevented tumor-induced inflammation and loss of fat and muscle mass. Fn14 signaling in the tumor, rather than host, is responsible for inducing this cachexia because tumors in Fn14- and TWEAK-deficient hosts developed cachexia that was comparable to that of wild-type mice. These results extend the role of Fn14 in wound repair and muscle development to involvement in the etiology of cachexia and indicate that Fn14 antibodies may be a promising approach to treat cachexia, thereby extending lifespan and improving quality of life for cancer patients.
Copyright © 2015 Elsevier Inc. All rights reserved.
| Journal | CELL |
| ISSN | 0092-8674 |
| Published | 10 Sep 2015 |
| Volume | 162 |
| Issue | 6 |
| Pages | 1365-78 |
| DOI | 10.1016/j.cell.2015.08.031 |
| Type | Journal Article |
| Sponsorship |
NHMRC
|